Socal Association for Biomedical and Pharmaceutical Advancements

Nonprofit profile at a glance

EIN
731627787
IRS 990 coverage
2016–2024
Forms available
Form 990 2024, Form 990-EZ 2023
Location
San Diego, CA, USA
Phone
8585318164
Rating
85
Verdict
STRONG
Rating confidence
Moderate
Sector
Professional Societies, Associations

Official website

Reported finances

Revenue
$262,586
Expenses
$227,141
Assets
$422,360
Liabilities
$0

Source: IRS Form 990. Selected filing: tax year 2024. Amounts in USD.

Leadership & pay

26 people listed

Executive titles in this filing

  • HUA GONG (BOARD VICE CHAIRMAN AND PRESIDENT)
  • JASON WANG (VICE CHAIR, PRESIDENT OF OC/LA CHAPTER)
  • DONGMEI HUANG (PRESIDENT ELECT OF THE SD CHAPTER)

People named in this filing

  • PETER Q HUANG (BOARD CHAIR)
  • STEPHANIE SHI (BOARD MEMBER)
  • HUAINA LI (BOARD MEMBER)

Selected names, not a complete roster or a statement of current roles. Open leadership details for the complete filed list.

Source: IRS Form 990. Selected filing: tax year 2024. Names and roles reflect this filing, not necessarily current officeholders.

Overview

Mission

Sabpa's primary mission and most significant activities are to promote science and innovation. (1). To provide forums for facilitating interaction and communcations among biotechinal proessionalsionals in glboal science and technology arena;(2). To promote interaction and collaboration in science and technology across the pacific regions; and(3). To stimulate and nurture the innovative ideas, cutting-edge technologies, entrepreneurship and bringing public awareness of the benefits of biomedical research.

What it reported doing in 2024

The 8th Annual Frontiers in Therapeutics and Diagnostics (FTD) Forum (March 23, 2024)Address: Hilton San Diego/Del Mar, 15575 Jimmy Durante Blvd, Del Mar, CASABPA FTD annually brings together the latest in groundbreaking research, cutting-edge drugs, and industry trends within the biopharma sector. The event's broad spectrum of topics provides a platform for local biotech companies to engage in vibrant discussions and valuable networking opportunities. The forthcoming 8th FTD Conference was set to shine a spotlight on three revolutionary domains in the field of metabolism disease and oncology: Glucagon-like peptide-1 (GLP-1), Antibody-Drug Conjugates (ADC), and Minimal Residual Disease (MRD), each representing the forefront of innovations in therapeutics and diagnostics. Program highlights are as follows:1. GLP-1 receptor agonists, from diabetes to obesity and beyond2. The rise of ADC - a biological missile, for targeted cancer therapy3. Reinventing drug discovery with AI-powered automation4. Frontiers in MRD detection to increase chance of cancer cure

Operating model

Revenue model
Earned-program. 78% of the money available for current operations came from fees and other program revenue.
Distribution model
Direct operator. The filing allocates 100% of reported program-service expenses outside its grant, affiliate-payment, and member-benefit lines. This expense classification does not rule out separately announced grant awards.

The verdict

STRONG - A large share of available resources goes toward mission work and the filed numbers largely add up. Some filing-based governance responses are negative or unanswered and total assets are small relative to annual expenses; liquid coverage is unknown.

Rating breakdown

  • Financial Efficiency: 79
  • Transparency & Controls: 92
  • Accountability: 88
  • Sustainability: 65
  • Growth: 100

Detailed rating inputs

Financial Efficiency

  • Mission deployment rate: 83.9%; rating input score 84
  • Program expense ratio: 96.4%; rating input score 96
  • Fundraising efficiency: Limited

Transparency & Controls

  • Consistency checks: 100%; rating input score 100; 64th percentile among comparable filings
  • Pay-setting controls: Limited
  • Foreign activity oversight: Limited
  • Grant itemization coverage: Limited
  • Major donor itemization: Yes; rating input score 100
  • Related-party transparency: Limited

Accountability

  • Independent voting board: 100%; rating input score 100; 63rd percentile among comparable filings
  • Governance controls: 5 of 7 controls in place; rating input score 71
    • Conflict-of-interest policy: Pass
    • Whistleblower policy: Pass
    • Document-retention policy: Pass
    • CEO compensation review process: NotApplicable
    • Other executive compensation review process: NotApplicable
    • Form 990 shared with the board: Pass
    • Board meeting minutes documented: Pass
    • Audit committee oversight: Missing
    • Independent financial-statement audit: Fail

Sustainability

  • Operating margin: 13.5%; rating input score 65; 65th percentile among comparable filings
  • Total-asset coverage ratio: 1.86; rating input score 57; 57th percentile among comparable filings
  • Liabilities to assets ratio: 0; rating input score 80; 80th percentile among comparable filings
  • Officer compensation ratio: 0%; rating input score 69; 69th percentile among comparable filings

Growth

  • Program expense growth: 3.3% per year; rating input score 100; 46th percentile among comparable filings
  • Revenue growth: 2.7% per year; rating input score 100; 39th percentile among comparable filings
  • Asset growth: 8.1% per year; rating input score 100; 60th percentile among comparable filings

Details

  • Where the money goes: 83.9% of revenue deployed · 96.4% of spending went to programs
  • Governance: 22 of 22 board members independent · 5 of 7 filing controls reported
  • Programs: 3 filed program accomplishments · $219K in reported program spending
  • Leadership: top reported pay $0 · 26 people listed
  • Consistency: 19 of 19 current checks pass
  • Schedules: 4 filed schedules · includes major donors
  • Filing history: 4 filing years from 2016 to 2024
  • Contacts: How to reach this organization
  • Grant readiness: Federal tax and exclusion status, award history, and grant-maker relationships.
  • People: Everyone the filings name, and which of them the filings identify by more than a name.

Key Signals

Signals prioritize questions for review. They are not findings of misconduct.

  • Review — Accountability: Governance controls: Independent financial-statement audit not reported.
  • Review — Sustainability: Total-asset coverage ratio scored 57/100.